The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that was not curable by surgery or radiation.
[OncLive, Inc.]
7753456
{7753456:nan}
apa
50
1
164278
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
